Author:
Dentali Francesco,Donadini Marco P,Clark Nathan,Crowther Mark A,Garcia David,Hylek Elaine,Witt Dan M,Ageno Walter,
Reference16 articles.
1. U.S. Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Available from http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070124.pdf . Accessed December 13, 2009.
2. U.S. Food and Drug Administration. Criteria and evidence to assess actual or potential bioequivalence problems. 21CFR320.33. Available from http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=320.33. Accessed December 13, 2009.
3. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital
4. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching
5. Evaluation of the Clinical and Economic Impact of a Brand Name–to-Generic Warfarin Sodium Conversion Program
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献